Artal Group’s Puma Biotechnology PBYI Stock Holding History

Artal Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$4.94M	–	131
2017 Q4	$4.94M	Buy	+50,000	New	+$5.6M	0.07%	70

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Artal Group's PBYI Position: Q1 2018 in Review

Artal Group sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 50,000 shares — an estimated $4.94M sold.

Artal Group first reported a position in PBYI in Q4 2017 and held it in 1 quarter. The position peaked at $4.94M in Q4 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

Artal Group reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
Artal Group sold 50,000 Puma Biotechnology shares in Q1 2018, an estimated $4.94M.
Artal Group first reported a position in Puma Biotechnology in Q4 2017 and held it in 1 quarter.
Artal Group's Puma Biotechnology position peaked at $4.94M in Q4 2017.
178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.